1. Pink Sheet

Accelerated Approval Reforms Give US FDA More Power And Flexibility – With Some Gaps

 
• By Sue Sutter

Pending legislation will give agency ability to require that confirmatory studies be underway at time of approval and expedited withdrawal process could allow FDA to skip a second advisory committee meeting, but Congress holds back on some agency requests for expanded authority.

Garden path
Omnibus funding measure includes expedited withdrawal procedures aimed at creating a clearer path for the FDA to get an accelerated approval drug off the market. • Source: Shutterstock

The fiscal year 2023 US government funding bill moving through Congress this week includes accelerated approval pathway reforms aimed at giving the Food and Drug Administration more authority to ensure the timely enrollment and completion of confirmatory trials.

However, the agency would appear to have considerable discretion in deciding when to require that a confirmatory study must be underway at the time of approval.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.